Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Want to cut your energy bills? Here’s how five experts are doing it 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
BRISBANE, Calif., May 31, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced today that Cameron Durrant, MD, chairman and CEO, will present a company overview at two investor conferences in early June.
Details of the presentations follow:
Primary Capital, The Investor Conference
Date: Sunday, June 4, 2017
Location: The Resort at Pelican Hill, Newport Beach, Calif.
7th Annual LD Micro Invitational
Date: Tuesday, June 6, 2017, 1:30 p.m. PT
Track: 5
Location: Luxe Sunset Boulevard Hotel, Los Angeles, Calif.
In addition, senior management will hold one-on-one meetings at the conferences. To schedule a meeting, contact MZ Group at [email protected].
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
